Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Becton Dickinson (NYSE:BDX) sees Q4 sales of $5.900 billion vs $5.912 billion analyst estimate.
Becton Dickinson (NYSE:BDX) narrows FY2025 sales outlook from $21.800 billion-$21.900 billion to $21.800 billion vs $21.863 bil...
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the enrollment of t...
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recog...
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—includ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
